Skip to main content
OpenTrials
Completed

NCT Number: NCT06516094

Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain

Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and security of the drug combination of Celecoxib / Pregabalin / Vitamin B versus Celecoxib + Vitamin B, versus Pregabalin + Vitamin B in the treatment of chronic low back pain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Low-back Pain Back Pain Chronic Pain Low Back Pain Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Laboratorio Silanes, S.A. de C.V.

Mexico City, 11000, Mexico

About this study

Researchers will compare the fixed-dose combination of Celecoxib/Pregabalin/Vitamin B versus Celecoxib + Vitamin B versus Pregabalin + Vitamin B for chronic low back pain. The adverse events related to the interventions would be registered in each follow up visit.

Participants will:

  • Be randomized into one of the 3 intervention groups (A,B,C) once a day for 12 weeks
  • If needed the dose could be escaleted twice a day.
  • Visit the clinic at weeks 2, 4, 8 and 12 for checkups and follow up

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Agree to participate in the study and give written informed consent
  • Subjects must have chronic low back pain with a high probability of a significant neuropathic component during 4 years or less (but not less than 3 months)
  • Patients with chronic low back pain reported as moderate to severe intensity (EVA ≥ 40 mm)
  • Patients with Neuropathic Pain Questionnaire (DN4) result ≥ 4
  • Women of childbearing potential under a medically acceptable method of contraception

Exclusion criteria

  • Patients participating in another clinical trial involving an investigational treatment or participation in one within 4 weeks prior to study start
  • Patients whose participation in the study may be influenced (employment relationship with the research site or sponsor, inmates, etc.)
  • At medical discretion, a disease that affects prognosis and prevents outpatient management, for example, but not limited to: end-stage cancer, kidney, heart, respiratory or liver failure, mental illness or with scheduled surgical or hospital procedures
  • History/presence of any disease or condition that, in the opinion of the Investigator, could pose a risk for the patient or confusing the efficacy and safety of the investigational product
  • Patients in whom the study drug is contraindicated for medical reasons
  • Patients with allergy or hypersensitivity to the active substance of the study drugs, related products or excipients
  • Pregnant women, women breastfeeding or planning a pregnancy during the conducting the study
  • Significant history of gastrointestinal diseases (e.g., gastric ulcer, Crohn's disease, Ulcerative Colitis, etc.)
  • Current treatment with opioids and/or NSAIDs including COX-2 inhibitors (except celecoxib), reported in clinical history in the last 24 hours to the signing of the informed consent
  • Patients who are receiving monoamineoxidase inhibitors (MAOIs) or who have received them in the course of the 2 weeks prior to signing the informed consent
  • Patients with a history of alcohol or drug abuse in the last year
  • Patients with a history of ischemic heart disease, peripheral artery disease, and/or cerebral vascular disease (including patients who have recently undergone coronary revascularization or angioplasty)
  • Patients with a history of seizures, epileptic status and/or grand mal seizures
  • History of chronic liver failure Child-Pugh A, B, and/or C
  • History of acute renal failure (glomerular filtration rate <30 ml/min/1.72 m2)
  • Patient with a history of chronic pain associated with fibromyalgia, Paget's disease or bone pain induced by metastatic cancer
  • History of major trauma to the lower back in the past 14 days
  • Low back pain due to a visceral disorder (e.g., dysmenorrhea, history of endometriosis)
  • Patients with a history of orthopedic surgery of the lumbar region secondary to chronic low back pain
  • Patients with symptoms suggestive of COVID-19 infection (fever, cough, dyspnea) and/or contact in the last 14 days with a suspected or positive patient for COVID-19

Treatment and study plan

Celecoxib+Pregabalin+Vitamin B fixed dose

Drug

One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day

Other names: Cele+Pre+Vit B

Celecoxib + Vitamin B fixed dose

Drug

One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day

Other names: Cele+Vit B

Pregabalin + Vitamin B fixed dose

Drug

One capsule of 150 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day

Other names: Pre+Vit B

Primary outcomes

  1. Comparison of the percentage change of Celecoxib / Pregabalin / Vitamin B Combination versus Celecoxib + Vitamin B versus Pregabalin + Vitamin B in the management of chronic low back pain through the visual analog pain scale (VAS).

    Time frame: 3 months

    The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the change porcentage will be measured and compared between treatment groups.

  2. Number of participants with treatment-related adverse events through the patient's diary record.

    Time frame: 3 months

    To describe the frequency, intensity and causality of the adverse events presented during the clinical trial by treatment group. The adverse events will be registered by the patient in the diary record. Each adverse event will be followed up at the discretion of the researcher.

Secondary outcomes

  1. To describe the sociodemographic characteristics of the patients included in the study by treatment group

    Time frame: 3 months

    A general description of sex, age, race, weight, height and BMI.

    • Body weight: should be obtained on a scale, with the patient without shoes, in a standing position it would be recorded in kilograms.
    • Height: must be obtained with a stadimeter, with the patient without shoes, in a standing position, the record will be in meters Height will be measured only at visit 0, and will be taken as a reference for measurement of BMI.
    • BMI: calculated with the formula: Weight/height2 and will be recorded in kg/m2.

    Weight and height will be combined to report BMI in kg/m^2

  2. Assess the proportion of patients who reported >30% improvement in pain intensity measured through VAS at 12 weeks per treatment group

    Time frame: 3 months

    The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the proportion of patiens with an improvement of pain >30% will be reported and compared between treatment groups.

  3. Assess the proportion of patients who reported >50% improvement in pain intensity measured through VAS at 12 weeks per treatment group

    Time frame: 3 months

    The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess pain intensity. At the end of the clinical trial the proportion of patiens with an improvement of pain >50% will be reported and compared between treatment groups.

  4. Assess at what time of follow-up the greatest reduction in pain intensity was achieved, measured through VAS, per treatment group.

    Time frame: 3 months

    The visual analog pain scale (VAS) is a straight line in which one end signifies absence of pain and the other means the worst pain imaginable. The researcher will apply the VAS scale to each patient at each visit to assess time of greatest reduction in pain intensity.

  5. Assess and compare the degree of physical disability due to low back pain, measured through the Oswestry disability questionnaire at 4 and 12 weeks per treatment group.

    Time frame: 3 months

    The Oswestry questionnaire has been designed to give us information as to how the back pain has affected the ability to manage everyday life of patients, it classifies QOL as: no disability, mild disability, moderate disability, severe disability and completely disabled. The disability degree would be compared.

  6. Assess and compare the degree of disability to perform daily activities due to low back pain, reported through Roland-Morris questionnaire at 4 and 12 weeks per group treatment

    Time frame: 3 months

    The Roland-Morris questionnaire has been designed to assess the activities of daily living functional mobility pain. A maximum score of 24 indicates the greatest degree of disability from pain. The disability degree would be compared.

  7. Assess and compare health status through the 5-level, 5-dimensions EuroQol questionnaire (EQ-5D-5L) at 12 weeks from baseline in each group of treatment

    Time frame: 3 months

    The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS)The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can image' and 'The worst health you can image'.

  8. Report the number of patients that required dose escalation

    Time frame: 3 months

    Dose escalation criteria:

    • Increase in VAS values compared to the previous visit.
    • Use of rescue medication at least in three consecutive occasions.
    • Percentage of adherence to treatment ≥ 80% The researcher will assess the need for dose escalation or not in each visit.

  9. Report the number of patients who require the use of rescue medication during the clinical trial by treatment group.

    Time frame: 3 months

    The rescue medication will be tramadol 50 mg:

    • The patient that considers the need for rescue medication must call the doctor, who will be in charge of applying the VAS scale by telephone. If the doctor considers it necessary, the taking of the rescue medication will be indicated.

  10. Report the number of patients who presented therapeutic failure during the study among the treatment groups

    Time frame: 3 months

    Therapeutic failure will be defined by the principal researcher previous medical consult, the following criteria must be present:

    • Increase in the parameters of the VAS scale at 12 weeks from baseline
    • ≥80% to adherence to treatment
    • The consumption of at least 2 doses of the designated group treatment
    • The need of use of the rescue medication during 24 consecutive hours
    • The absence of comorbidities that could increase the pain (knew traumatism during the clinical trial)

  11. To report the percentage of therapeutic adherence at 12 weeks of intervention by group of treatment.

    Time frame: 3 months

    Therapeutic adherence will be defined by the principal researcher. Adherence to treatment will be defined as a consumption ≥ 80% of the doses that the patient should have ingested at the time of the corresponding evaluation.

  12. Blood concentration of BUN of the patients included in the study by treatment group

    Time frame: 3 months

    A blood sample will be taken in each visit reporting BUN parameters. Comparisons of serum levels between groups will be made.

  13. Blood concentration of glucose of the patients included in the study by treatment group

    Time frame: 3 months

    A blood sample will be taken in each visit reporting glucose parameters. Comparisons of serum levels between groups will be made.

  14. Blood concentration of urea of the patients included in the study by treatment group

    Time frame: 3 months

    A blood sample will be taken in each visit reporting urea parameters. Comparisons of serum levels between groups will be made.

  15. Blood concentration of creatinin of the patients included in the study by treatment group

    Time frame: 3 months

    A blood sample will be taken in each visit reporting creatinin parameters. Comparisons of serum levels between groups will be made.

  16. Blood concentration of Alkaline Phosphatase of the patients included in the study by treatment group

    Time frame: 3 months

    A blood sample will be taken in each visit reporting Alkaline Phosphatase parameters. Comparisons of serum levels between groups will be made.

  17. Blood concentration of total bilirrubin of the patients included in the study by treatment group

    Time frame: 3 months

    A blood sample will be taken in each visit reporting total bilirrubin parameters. Comparisons of serum levels between groups will be made.

Sponsors and collaborators

Lead sponsor

Laboratorios Silanes S.A. de C.V.

Industry

Registry information

Official study title

Efficacy and Safety Study of Celecoxib / Pregabalin / Vitamin B Fixed Dose Combination Versus Celecoxib + Vitamin B Versus Pregabalin + Vitamin B in the Management of Chronic Low Back Pain Mixed Component

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 23, 2024
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.